| Current Price | $3.01 | Mkt Cap | $1.4B |
|---|---|---|---|
| Open | $3.00 | P/E Ratio | 0.00 |
| Prev. Close | $3.01 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $2.97 - $3.10 | Volume | 1,849,174 |
| 52-Wk Range | $2.12 - $8.86 | Avg. Daily Vol. | 2,609,055 |
23andMe, Inc., headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, 23andMe's mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple Food and Drug Administration authorizations for genetic health risk reports. 23andMe has created the world's largest crowdsourced platform for genetic research, with 80% of its customers electing to participate.
| Current Price | $3.01 | Mkt Cap | $1.4B |
|---|---|---|---|
| Open | $3.00 | P/E Ratio | 0.00 |
| Prev. Close | $3.01 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $2.97 - $3.10 | Volume | 1,849,174 |
| 52-Wk Range | $2.12 - $8.86 | Avg. Daily Vol. | 2,609,055 |
The best Bull and Bear pitches based on recency and number of recommendations.
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about ME.
Recs
UncannyHoosier
(29.65)
Submitted: 11/7/2022 2:24:04 PM :
Start Price:
$2.94
NASDAQ:ME Score:
-1.23
upcoming
Recs
Har1en
(99.41)
Submitted: 10/1/2022 5:18:47 PM :
Start Price:
$2.95
NASDAQ:ME Score:
-6.85
Just heard the CEO speak, and I'm with her on the idea that the only way genomics moves forward is with consumer control over their own data. 23andMe seems to be best positioned in the industry, and they seem to be actually helping people live better, fuller, longer lives. However, this company is a money pit. I think if they can figure out how to actually stabilize in the next 24 months, we are off to the races. Otherwise... they're heading for pain. Raising money in this market downturn will be hard. Individual investors may not see great returns because of this, however, for humanity, I hope this company survives and does great things.
Recs
TMFJaguar
(44.43)
Submitted: 1/14/2022 1:51:35 PM :
Start Price:
$5.00
NASDAQ:ME Score:
-25.97
High risk because the core business doesn't generate positive cash flow. High reward because the company should have the highest quality genetic dataset around. With advancement in data analytics over the next 5 to 10 years, I don't see how this won't be valuable. At its current price, it's trading at around a $2.3 billion market cap with over $700 million in cash, substantial cushion and downside mitigation. Not a sure thing, but if a drug is a winner, this will likely be a multibagger.
Find the members with the highest scoring picks in ME.
chammond55 (94.99) Score: +60.76
The Score Leader is the player with the highest score across all their picks in ME.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| elektragreen159 | 80.49 | 8/13/2021 |
|
5Y | $7.63 | -60.55% | -11.75% | +48.80 | 0 Comment | |
| TMFJoryko | 81.91 | 6/10/2022 |
|
5Y | $2.16 | +39.35% | +0.77% | +38.58 | 0 Comment | |
| Under5b | < 20 | 9/27/2022 |
|
5Y | $3.06 | -1.63% | +6.83% | +8.47 | 0 Comment | |
| MylesPatrick | 82.85 | 11/11/2022 |
|
1Y | $3.19 | -5.64% | -0.52% | +5.12 | 0 Comment | |
| UncannyHoosier | 29.65 | 11/7/2022 |
|
5Y | $2.94 | +2.38% | +3.62% | -1.23 | 1 Comment | |
| valari25 | 99.84 | 11/21/2022 |
|
5Y | $2.90 | +3.97% | -0.34% | -4.31 | 0 Comment | |
| Under5 | 60.83 | 10/4/2022 |
|
5Y | $3.07 | -1.95% | +4.73% | -6.69 | 0 Comment | |
| Har1en | 99.41 | 10/3/2022 |
|
5Y | $2.95 | +2.03% | +8.88% | -6.85 | 1 Comment | |
| XMFFlygal | 96.72 | 11/22/2022 |
|
3W | $2.82 | +6.93% | -1.44% | -8.37 | 0 Comment | |
| tradingfool1 | 27.35 | 2/2/2022 |
|
5Y | $4.57 | -34.14% | -13.43% | -20.70 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
